Home » Stocks » CDNA

CareDx, Inc. (CDNA)

Stock Price: $71.65 USD 3.68 (5.41%)
Updated May 18, 2021 1:44 PM EDT - Market open
Market Cap 3.41B
Revenue (ttm) 221.21M
Net Income (ttm) -13.58M
Shares Out 51.18M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend $1.58
Dividend Yield 2.20%
Trading Day May 18
Last Price $71.65
Previous Close $67.97
Change ($) 3.68
Change (%) 5.41%
Day's Open 68.35
Day's Range 67.62 - 72.53
Day's Volume 257,109
52-Week Range 29.03 - 99.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.

Other stocks mentioned: EXAS, GH
1 week ago - The Motley Fool

CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Strong start to 2021, raising full year guidance Strong start to 2021, raising full year guidance

1 week ago - GlobeNewsWire

Renowned transplant clinicians to present 15 heart abstracts at ISHLT Renowned transplant clinicians to present 15 heart abstracts at ISHLT

3 weeks ago - GlobeNewsWire

Current Medicare coverage for CareDx services remains unchanged under the new universal coverage policy Current Medicare coverage for CareDx services remains unchanged under the new universal coverage p...

3 weeks ago - GlobeNewsWire

Leading transplant clinicians to present data in seven abstracts at International Society of Heart and Lung Transplantation Annual Meeting Leading transplant clinicians to present data in seven abstract...

3 weeks ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

3 weeks ago - GlobeNewsWire

Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians

4 weeks ago - GlobeNewsWire

Company to showcase its latest integrated solutions for improving care across the whole transplant journey Company to showcase its latest integrated solutions for improving care across the whole transpl...

1 month ago - GlobeNewsWire

Initial projects underway for global pharmaceutical company Initial projects underway for global pharmaceutical company

1 month ago - GlobeNewsWire

CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program CareDx to Host Virtual Exhibitor Showcase and Continuing Medical Education Program

1 month ago - GlobeNewsWire

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

Other stocks mentioned: NTRA, VCYT
1 month ago - The Motley Fool

CareDx Builds for the Future by Investing in Talent CareDx Builds for the Future by Investing in Talent

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

2 months ago - GlobeNewsWire

This under-the-radar diagnostics company is thriving yet reasonably priced.

Other stocks mentioned: GH
2 months ago - The Motley Fool

TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx's focus on the patient journey TX Connect adds 19,000 patient referrals for kidney transplant and continues CareDx's f...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 months ago - GlobeNewsWire

Benzinga recently spoke with CareDx Inc (NASDAQ: CDNA) CEO Reginald Seeto to discuss the diagnostics surveillance solution provider's business, financials, market opportunity, alliances and future focus...

2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

2 months ago - GlobeNewsWire

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

3 months ago - GlobeNewsWire

CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentatio...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically...

3 months ago - GlobeNewsWire

Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening the moat wi...

4 months ago - GlobeNewsWire

CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplan...

4 months ago - GlobeNewsWire

AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx's Innovation in Multi-Modality Surveillance Care AlloID is a Transplant Patient-Specific Metagenom...

4 months ago - GlobeNewsWire

CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, Établisseme...

4 months ago - GlobeNewsWire

CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind for CareDx.

4 months ago - Seeking Alpha

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.

Other stocks mentioned: CRWD, MED, MTSI, ZS
4 months ago - Zacks Investment Research

We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.

Other stocks mentioned: FLGT, OMI, QDEL
4 months ago - Zacks Investment Research

Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients Partners with large transplant coalition to expand access to lifesaving medications for...

4 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in CareDx (CDNA).

4 months ago - Zacks Investment Research

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Other stocks mentioned: HROW, BMXMF, AMEH
5 months ago - Zacks Investment Research

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

6 months ago - GlobeNewsWire

Research from Johns Hopkins , U niversity of Maryland, and Cedars Sinai Shows AlloSure May Signal BK Virus Progression in Transplant Patients

6 months ago - GlobeNewsWire

CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwest Virtual Kidney Walk CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwes...

6 months ago - GlobeNewsWire

CareDx, Inc. (CDNA) CEO Peter Maag on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

CareDx (CDNA) delivered earnings and revenue surprises of 266.67% and 0.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

CareDx, Inc's (CDNA) CEO Peter Maag On Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

6 months ago - GlobeNewsWire

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meeting General nephrologists show a growing interest in AlloSure with 11...

6 months ago - GlobeNewsWire

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup S... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 17, 2014
CEO
Peter Maag
Employees
456
Stock Exchange
NASDAQ
Ticker Symbol
CDNA
Full Company Profile

Financial Performance

In 2020, CareDx's revenue was $192.19 million, an increase of 51.25% compared to the previous year's $127.07 million. Losses were -$18.71 million, -14.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CareDx stock is "Strong Buy." The 12-month stock price forecast is 97.80, which is an increase of 36.50% from the latest price.

Price Target
$97.80
(36.50% upside)
Analyst Consensus: Strong Buy